Genocea Biosciences Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Genocea Biosciences has been growing earnings at an average annual rate of 13.2%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 40.6% per year.
Belangrijke informatie
13.2%
Groei van de winst
32.9%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | 40.6% |
Rendement op eigen vermogen | -300.3% |
Nettomarge | -1,946.2% |
Laatste winstupdate | 31 Mar 2022 |
Recente prestatie-updates uit het verleden
Recent updates
Here's Why Shareholders May Want To Be Cautious With Increasing Genocea Biosciences, Inc.'s (NASDAQ:GNCA) CEO Pay Packet
Jun 17What Type Of Returns Would Genocea Biosciences'(NASDAQ:GNCA) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Feb 18How Much Of Genocea Biosciences, Inc. (NASDAQ:GNCA) Do Institutions Own?
Jan 14Opbrengsten en kosten
Hoe Genocea Biosciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
31 Mar 22 | 2 | -37 | 15 | 44 |
31 Dec 21 | 2 | -33 | 15 | 40 |
30 Sep 21 | 2 | -35 | 15 | 37 |
30 Jun 21 | 0 | -36 | 15 | 35 |
31 Mar 21 | 1 | -43 | 15 | 33 |
31 Dec 20 | 1 | -44 | 14 | 34 |
30 Sep 20 | 1 | -38 | 14 | 33 |
30 Jun 20 | 1 | -41 | 13 | 32 |
31 Mar 20 | 0 | -36 | 12 | 30 |
31 Dec 19 | 0 | -39 | 12 | 27 |
30 Sep 19 | 0 | -29 | 12 | 26 |
30 Jun 19 | 0 | -30 | 13 | 26 |
31 Mar 19 | 0 | -27 | 14 | 24 |
31 Dec 18 | 0 | -28 | 14 | 25 |
30 Sep 18 | 0 | -39 | 14 | 58 |
30 Jun 18 | 0 | -48 | 14 | 52 |
31 Mar 18 | 0 | -59 | 13 | 46 |
31 Dec 17 | 0 | -57 | 13 | 39 |
30 Sep 17 | 0 | -62 | 15 | 0 |
30 Jun 17 | 0 | -58 | 15 | 0 |
31 Mar 17 | 0 | -54 | 15 | 0 |
31 Dec 16 | 0 | -50 | 15 | 0 |
30 Sep 16 | 0 | -44 | 15 | 0 |
30 Jun 16 | 1 | -41 | 15 | 0 |
31 Mar 16 | 1 | -40 | 15 | 0 |
31 Dec 15 | 1 | -42 | 14 | 0 |
30 Sep 15 | 1 | -44 | 13 | 0 |
30 Jun 15 | 1 | -43 | 12 | 0 |
31 Mar 15 | 0 | -40 | 11 | 0 |
31 Dec 14 | 0 | -35 | 10 | 0 |
30 Sep 14 | 0 | -31 | 9 | 0 |
30 Jun 14 | 0 | -27 | 8 | 0 |
31 Mar 14 | 0 | -25 | 6 | 0 |
31 Dec 13 | 1 | -22 | 5 | 0 |
30 Sep 13 | 1 | -21 | 4 | 0 |
30 Jun 13 | 1 | -20 | 4 | 0 |
31 Mar 13 | 2 | -17 | 4 | 0 |
31 Dec 12 | 2 | -15 | 4 | 0 |
Kwaliteitswinsten: GNCA.Q is currently unprofitable.
Groeiende winstmarge: GNCA.Q is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: Insufficient data to determine if GNCA.Q's year-on-year earnings growth rate was positive over the past 5 years.
Versnelling van de groei: Unable to compare GNCA.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: GNCA.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Rendement op eigen vermogen
Hoge ROE: GNCA.Q has a negative Return on Equity (-300.29%), as it is currently unprofitable.